Irish pharmaceuticals group Uniphar has today announced a deal to buy US-based RRD International.
RRD is a US based pharmaceutical advisory group providing outsourced strategic consulting and execution services throughout the early stages of a products development.
RRD works with companies from pre-clinical stages up o licensing, across a broad range of product classes and therapeutic areas and has supported the FDA regulatory approval of over 100 assets.
Uniphar said today's deal along with the previously announced acquisition of Diligent Health Solutions creates a unique capability to design and implement compliant, patient centric products across the US.
Ger Rabbette, CEO of Uniphar, said that becoming a truly global partner for its clients in this area is an important strategic objective for the group.
"The highly experienced RRD team brings deep US regulatory insights which will further accelerate our growth towards market leadership. The acquisition marks an important strategic milestone for the group and grows our US workforce to close to 170 colleagues," Mr Rabbette said.
